Navigation Links
Plurality Completes R&D of its HAL-256 Multicore Processor
Date:2/26/2008

The 256-core Chip Caters to Next-Generation Technologies Requiring Massive

Parallel Processing Capabilities.

EMBEDDED WORLD 2008, NUREMBERG, Germany, February 26 /PRNewswire/ -- Plurality Ltd. announced today that it has completed the research and development of HAL-256, the first solution to emerge from its HyperCore Architecture Line (HAL) of multicore processors.

Igor Pe'er, Acting CEO of Plurality said, "The industry is ambitiously undertaking the challenge of how to solve the issue of massive parallel processing. We believe Plurality's solution achieves the highest possible performance per price and per watt in the market to date, uniquely positioning the HAL-256 multicore chip as a 'general purpose accelerator,' sometimes even enabling the replacement of an ASIC solution with a fully programmable, remotely updatable software solution. Plurality expects to deliver a substantial product to market in 2009."

"Plurality is delivering a performance-breakthrough on a chip," said Peleg Avieli, Vice President Engineering. "Within our HAL-256 multicore processor lies a highly complex and sophisticated solution that is very simple for customers to integrate and apply, combining a wish-list of Relative Advantages:
- Friendly, 'near serial' programmability

- Scalable high performance on a compact chip

- Unprecedented performance for the money, and

- Low power consumption." In November 2007, BVR Systems (OTC Bulletin Board: BVRSF), announced that it entered a strategic cooperation agreement with Plurality for access to its multicore technology in order to significantly fortify its training and simulation solutions capabilities. BVR is a world leader in the development, manufacture and delivery of training and simulation turnkey projects for the military and civilian markets.

The Company is also engaged in advanced talks with a strategic customer regarding a high-volume application.

Plurality is about to complete an investment round that will finance the production and commercialization of the HAL-256.

Forward-looking Statements: This release contains forward-looking statements and projections based on assessments and assumptions. These statements and projections are not a guarantee of results and are subject to inherent risks and uncertainties.

About Plurality

Plurality Ltd. is the developer of the HyperCore Processor, a viable multicore processing solution that greatly speeds up complex processing and applications. The HyperCore Processor is a scalable, easily programmable, general-purpose, multicore processor that addresses the performance required by modern algorithms and applications while exploiting their inherent parallelism.

For Further Information Contact:

Karen Gold Anisfeld

+972-9-746-3956

media@plurality.com

http://www.plurality.com


'/>"/>
SOURCE Plurality LTD
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. H2Diesel Completes 3 Million Gallon Per Year Pilot Facility
2. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Carrington Completes $8 Million Financing
5. Proteon Therapeutics Completes $12 Million Financing and Hires CFO
6. New Brunswick Scientific Completes Merger Transaction with Eppendorf
7. Kiwa Bio-Tech Completes 1st Stage of Shandong Factory Upgrading
8. PAREXEL International Completes Acquisition of APEX International Clinical Research Co., Ltd.
9. Optherion, Inc. Completes $37 Million Start Up Financing
10. Companys Partner Completes Trial Production of a New Antiviral Medicine
11. American Oriental Bioengineering Completes Acquisition of Guangxi Boke Pharmaceutical Company Ltd.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... 16, 2017   Biostage, Inc. (Nasdaq: ... company developing bioengineered organ implants to treat cancers and ... announced today the closing on February 15, 2017 of ... common stock and warrants to purchase 20,000,000 shares of ... The offering was priced at $0.40 per share of ...
(Date:2/16/2017)...  Dermata Therapeutics, LLC, a biotechnology company developing ... of dermatological diseases, today announced it has completed ... into a $5 million credit facility with Silicon ... capital for general corporate purposes to further Dermata,s ... of serious diseases treated by dermatologists.   ...
(Date:2/16/2017)...  Windtree Therapeutics, Inc. (Nasdaq: WINT ... KL4 surfactant therapies for respiratory diseases, announced today ... that aerosolized KL4 surfactant reduced lung inflammation and ... model. The Company believes that these preclinical data ... supports the role of KL4 surfactant as a ...
(Date:2/16/2017)... ... February 16, 2017 , ... ... industry leading Biochemistry Services specifically targeting the rapidly growing needs of the ... the biochemical and biosimilar characterization , product-related impurity characterization, aggregation ...
Breaking Biology Technology:
(Date:1/23/2017)... 2017  The latest mobile market research from Acuity ... dramatically. The quarterly average price of a biometric smartphone ... Q4 2016.  There are now 120 sub-$150 models on ... from just 28 a year ago at an average ... Maxine Most , Acuity Market Intelligence Principal, "Biometric Smartphones ...
(Date:1/18/2017)...  In vitro diagnostic (IVD) companies were very active ... and Kalorama Information expects that trend to continue – ... Generally, uncertainty in reimbursement and healthcare reform in ... the acquisitions landscape. Instead of looking to buy technology, ... outside of their home country and also to increase ...
(Date:1/12/2017)...  New research undertaken by Fit Small Business ... participants were simply asked which office technology had they not ... standard issue.  Insights on what will be key ... futurists and industry leaders including Penelope Trunk , ... Some of these findings included; ...
Breaking Biology News(10 mins):